Oxford BioMedica plc (OXB) Now Covered by Peel Hunt
Investment analysts at Peel Hunt began coverage on shares of Oxford BioMedica plc (LON:OXB) in a report issued on Tuesday. The brokerage set a “buy” rating and a GBX 13 ($0.18) price target on the biopharmaceutical company’s stock. Peel Hunt’s target price indicates a potential upside of 48.57% from the stock’s previous close.
OXB has been the subject of several other reports. N+1 Singer upped their price target on shares of Oxford BioMedica plc from GBX 8.70 ($0.12) to GBX 10.20 ($0.14) and gave the stock a “hold” rating in a report on Thursday, August 31st. Jefferies Group LLC reiterated a “buy” rating and set a GBX 13 ($0.18) price target on shares of Oxford BioMedica plc in a report on Thursday, August 31st. Finally, Shore Capital reiterated a “not rated” rating on shares of Oxford BioMedica plc in a report on Thursday, July 13th.
Shares of Oxford BioMedica plc (LON:OXB) traded down 1.80% during trading on Tuesday, hitting GBX 8.75. The stock had a trading volume of 1,397,403 shares. Oxford BioMedica plc has a 12-month low of GBX 2.98 and a 12-month high of GBX 11.25. The stock’s market capitalization is GBX 270.22 million. The stock’s 50-day moving average is GBX 8.85 and its 200-day moving average is GBX 6.66.
ILLEGAL ACTIVITY WARNING: “Oxford BioMedica plc (OXB) Now Covered by Peel Hunt” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/09/24/oxford-biomedica-plc-oxb-now-covered-by-peel-hunt.html.
In other Oxford BioMedica plc news, insider Lorenzo Tallarigo acquired 29,685 shares of Oxford BioMedica plc stock in a transaction that occurred on Friday, September 22nd. The shares were bought at an average price of GBX 9 ($0.12) per share, with a total value of £2,671.65 ($3,602.06). Also, insider Martin Diggle acquired 660,000 shares of Oxford BioMedica plc stock in a transaction that occurred on Thursday, July 13th. The stock was acquired at an average cost of GBX 9 ($0.12) per share, for a total transaction of £59,400 ($80,086.29). Insiders have bought 1,359,372 shares of company stock valued at $11,884,661 over the last quarter.
Oxford BioMedica plc Company Profile
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.
Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with MarketBeat.com's FREE daily email newsletter.